{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:37:35Z","timestamp":1781163455956,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["MH091037"],"award-info":[{"award-number":["MH091037"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["MH52711"],"award-info":[{"award-number":["MH52711"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000297","name":"FRAXA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009670","name":"NARSAD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation, Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Danish Council for Independent Research","doi-asserted-by":"publisher","award":["DFF-4004-00188"],"award-info":[{"award-number":["DFF-4004-00188"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.neuropharm.2017.09.026","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T16:45:49Z","timestamp":1506012349000},"page":"43-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in Fmr1 KO mice"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7132-6532","authenticated-orcid":false,"given":"Manavi","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep K.","family":"Kurup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla J.","family":"Lundbye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Karina","family":"Hugger Toft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeemin","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Benedict","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Kamceva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tue G.","family":"Banke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Lombroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.09.026_bib1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1021\/cn900036x","article-title":"Neuropeptide release is impaired in a mouse model of fragile X mental retardation syndrome","volume":"1","author":"Annangudi","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nrn1667","article-title":"From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome","volume":"6","author":"Bagni","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib3","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1172\/JCI63141","article-title":"Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics","volume":"122","author":"Bagni","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.tins.2004.04.009","article-title":"The mGluR theory of fragile X mental retardation","volume":"27","author":"Bear","year":"2004","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib5","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1038\/tp.2012.63","article-title":"The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications","volume":"2","author":"Carty","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.026_bib6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.neuropharm.2013.05.018","article-title":"BDNF in fragile X syndrome","volume":"76","author":"Castren","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.026_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ajhg.2009.09.007","article-title":"Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA","volume":"85","author":"Coffee","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0091-3057(80)90067-2","article-title":"Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines","volume":"13","author":"Crawley","year":"1980","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cell.2011.06.013","article-title":"FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism","volume":"146","author":"Darnell","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2017.09.026_bib10","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1073\/pnas.1219383110","article-title":"Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486","volume":"110","author":"Dolan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/pr.110.003053","article-title":"Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders","volume":"64","author":"Goebel-Goody","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1601-183X.2012.00781.x","article-title":"Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model","volume":"11","author":"Goebel-Goody","year":"2012","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib13","doi-asserted-by":"crossref","first-page":"10624","DOI":"10.1523\/JNEUROSCI.0402-10.2010","article-title":"Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome","volume":"30","author":"Gross","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/jnc.12323","article-title":"Cellular distribution of AMPA receptor subunits and mGlu5 following acute and repeated administration of morphine or methamphetamine","volume":"126","author":"Herrold","year":"2013","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib15","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1073\/pnas.122205699","article-title":"Altered synaptic plasticity in a mouse model of fragile X mental retardation","volume":"99","author":"Huber","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature11764","article-title":"Neurodevelopmental disorders: signalling pathways of fragile X syndrome","volume":"492","author":"Jayaseelan","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.09.026_bib17","first-page":"8136925","article-title":"Role of striatal-enriched tyrosine phosphatase in neuronal function","author":"Kamceva","year":"2016","journal-title":"Neural Plast."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib18","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1523\/JNEUROSCI.4462-11.2012","article-title":"Dendritic BDNF synthesis is required for late-phase spine maturation and recovery of cortical responses following sensory deprivation","volume":"32","author":"Kaneko","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5582\/irdr.2014.01024","article-title":"Modeling fragile X syndrome in the Fmr1 knockout mouse","volume":"3","author":"Kazdoba","year":"2014","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib20","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1073\/pnas.1417423112","article-title":"STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease","volume":"112","author":"Kurup","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/hmg\/10.4.329","article-title":"Evidence that fragile X mental retardation protein is a negative regulator of translation","volume":"10","author":"Laggerbauer","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib22","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1523\/JNEUROSCI.2624-07.2007","article-title":"Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome","volume":"27","author":"Lauterborn","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/191474a0","article-title":"Social dominance in inbred mouse strains","volume":"191","author":"Lindzey","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.09.026_bib24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/jnnp.6.3-4.154","article-title":"A\u00a0pedigree of mental defect showing sex-linkage","volume":"6","author":"Martin","year":"1943","journal-title":"J.\u00a0Neurol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.026_bib25","doi-asserted-by":"crossref","first-page":"e9706","DOI":"10.1371\/journal.pone.0009706","article-title":"GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism","volume":"5","author":"Mines","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.09.026_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1601-183X.2008.00452.x","article-title":"Social approach in genetically engineered mouse lines relevant to autism","volume":"8","author":"Moy","year":"2009","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib50","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cell.2008.07.031","article-title":"The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP","volume":"134","author":"Napoli","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2017.09.026_bib27","doi-asserted-by":"crossref","first-page":"24274","DOI":"10.1074\/jbc.M111683200","article-title":"Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420","volume":"277","author":"Nguyen","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbr.2013.01.002","article-title":"Monogenic mouse models of social dysfunction: implications for autism","volume":"251","author":"Oddi","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib29","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0278-5846(89)90047-X","article-title":"Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety","volume":"13","author":"Onaivi","year":"1989","journal-title":"Prog. neuro-psychopharmacology Biol. psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.026_bib30","doi-asserted-by":"crossref","first-page":"11618","DOI":"10.1523\/JNEUROSCI.0012-13.2013","article-title":"Distinct roles for somatically and dendritically synthesized brain-derived neurotrophic factor in morphogenesis of dendritic spines","volume":"33","author":"Orefice","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nn989","article-title":"NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling","volume":"6","author":"Paul","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","article-title":"Modification of seizure activity by electrical stimulation. II. Motor seizure","volume":"32","author":"Racine","year":"1972","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib33","doi-asserted-by":"crossref","first-page":"e107591","DOI":"10.1371\/journal.pone.0107591","article-title":"Rapid Golgi analysis method for efficient and unbiased classification of dendritic spines","volume":"9","author":"Risher","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.neuropharm.2017.09.026_bib34","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1007\/s12035-015-9335-7","article-title":"BDNF induces striatal-enriched protein tyrosine phosphatase 61 degradation through the proteasome","volume":"53","author":"Saavedra","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nn1503","article-title":"Regulation of NMDA receptor trafficking by amyloid-beta","volume":"8","author":"Snyder","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"8 Spec No","key":"10.1016\/j.neuropharm.2017.09.026_bib36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/FBP.0000000000000152","article-title":"Hyperactivity and lack of social discrimination in the adolescent Fmr1 knockout mouse","volume":"26","author":"Sorensen","year":"2015","journal-title":"Behav Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/aur.168","article-title":"Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses","volume":"4","author":"Spencer","year":"2011","journal-title":"Autism Res. official J. Int. Soc. Autism Res."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1601-183X.2005.00123.x","article-title":"Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome","volume":"4","author":"Spencer","year":"2005","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib39","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1523\/JNEUROSCI.3038-15.2016","article-title":"Dysregulated NMDA-receptor signaling inhibits long-term depression in a mouse model of fragile X syndrome","volume":"36","author":"Toft","year":"2016","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib40","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1037\/a0025202","article-title":"The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide","volume":"125","author":"Veeraragavan","year":"2011","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mcn.2009.06.009","article-title":"New insights into the role of brain-derived neurotrophic factor in synaptic plasticity","volume":"42","author":"Waterhouse","year":"2009","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.conb.2009.03.011","article-title":"Protein translation in synaptic plasticity: mGluR-LTD, Fragile X","volume":"19","author":"Waung","year":"2009","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib43","doi-asserted-by":"crossref","first-page":"e1001923","DOI":"10.1371\/journal.pbio.1001923","article-title":"Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease","volume":"12","author":"Xu","year":"2014","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/mp.2016.163","article-title":"Inhibition of STEP61 ameliorates deficits in mouse and hiPSC-based schizophrenia models","author":"Xu","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.neuropharm.2017.09.026_bib45","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00018-015-2057-1","article-title":"Inhibition of the tyrosine phosphatase STEP restores BDNF expression and reverses motor and cognitive deficits in phencyclidine-treated mice","volume":"73","author":"Xu","year":"2016","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib46","doi-asserted-by":"crossref","first-page":"20942","DOI":"10.1074\/jbc.M112.368654","article-title":"Striatal-enriched protein-tyrosine phosphatase (STEP) regulates Pyk2 kinase activity","volume":"287","author":"Xu","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib47","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.neuropharm.2005.06.004","article-title":"Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP","volume":"49","author":"Yan","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.026_bib48","doi-asserted-by":"crossref","first-page":"19014","DOI":"10.1073\/pnas.1013543107","article-title":"Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model","volume":"107","author":"Zhang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.026_bib49","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1523\/JNEUROSCI.2666-08.2008","article-title":"The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation","volume":"28","author":"Zhang","year":"2008","journal-title":"J.\u00a0Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T07:58:54Z","timestamp":1535356734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817304434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":50,"alternative-id":["S0028390817304434"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.026","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in Fmr1 KO mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}